SBM Sirona Biochem Corp.

Sirona Biochem Update to Shareholders on Financial Status and Operations

Sirona Biochem Update to Shareholders on Financial Status and Operations

VANCOUVER, British Columbia, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (“Sirona”) wishes to provide shareholders with a critical update on the company’s financial position and recent corporate developments.

The convertible debenture financing announced on April 22, 2025, did not attract sufficient investor participation to proceed successfully. This outcome reflects the challenges encountered during a similar financing one year prior. Over the past two years, Vancouver-based management has operated without salary and has personally contributed funds to sustain essential operations.

After an extensive search for strategic investment, Sirona entered into an investment agreement with Promura GmbH, also announced on April 22, 2025. This decision followed a detailed due diligence process, including a review of Promura GmbH and its principal, Mr. Markus Burbach. Despite multiple assurances and repeated delays, the funds committed under this agreement were never received. Sirona has now concluded that the investment will not materialize.

In light of limited financing options, Sirona has made the difficult decision to allow for the orderly liquidation of its wholly owned subsidiary, TFChem, in accordance with French bankruptcy regulations. All laboratory operations have ceased, and the facility is now permanently closed. Sirona is also facing ongoing financial pressures, which led to the issuance of a cease trade order on March 7, 2025.

Additionally, Sirona has been informed that Allergan Aesthetics will not be proceeding with the license agreement announced on June 13, 2022, regarding the commercialization of TFC-1067. Sirona values the experience gained through this collaboration and appreciates the opportunity to have worked with a global leader in medical aesthetics.

Despite ongoing and significant challenges, management acknowledges that the commercial potential of its proprietary technologies remains uncertain. Nevertheless, it is evaluating structural and financial options that could, if feasible, support their future development.

About Sirona Biochem

Sirona is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.

Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit .

Investor Enquiries:

Christopher Hopton

Chief Financial Officer

Phone: (604) 641-4466

Email:

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward Looking Statements

This news release includes certain statements that may be deemed “forward-looking statements”. All statements in this new release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company’s management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.



EN
01/08/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sirona Biochem Corp.

 PRESS RELEASE

Sirona Biochem Update to Shareholders on Financial Status and Operatio...

Sirona Biochem Update to Shareholders on Financial Status and Operations VANCOUVER, British Columbia, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (“Sirona”) wishes to provide shareholders with a critical update on the company’s financial position and recent corporate developments. The convertible debenture financing announced on April 22, 2025, did not attract sufficient investor participation to proceed successfully. This outcome reflects the challenges encountered during a similar financing one year prior. Over the past two years, Vancouver-based ...

 PRESS RELEASE

Sirona Biochem Announces Debenture Financing

Sirona Biochem Announces Debenture Financing VANCOUVER, British Columbia, April 22, 2025 (GLOBE NEWSWIRE) -- . (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona” or the “Company”) is pleased to announce a non-brokered private placement offering of unsecured, convertible debentures (the “Convertible Debentures”). The Convertible Debentures will be offered in units (the “Debenture Units”) at a price of $1,000 per Debenture Unit for aggregate gross proceeds of up to $400,000 (the “Offering”). The Company plans to use the proceeds of the Offering for general corporate purposes. Each Debenture Un...

 PRESS RELEASE

Sirona Biochem Secures Strategic Investment Agreements and New Joint V...

Sirona Biochem Secures Strategic Investment Agreements and New Joint Venture with Promura GmbH VANCOUVER, British Columbia, April 22, 2025 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”), a biotechnology company specializing cosmetic ingredients and new drug discoveries, is pleased to announce the successful execution of a strategic investment agreement with Promura GmbH, a German-based investor. The agreement includes the private placement of $3 million CAD in unsecured, 12% convertible debentures, by Promura GmbH. In addition to the convertible ...

 PRESS RELEASE

Sirona Biochem Showcases TFC-1326 in Stonegate Healthcare’s Landmark R...

Sirona Biochem Showcases TFC-1326 in Stonegate Healthcare’s Landmark Report VANCOUVER, British Columbia, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) is excited to announce that its cutting-edge anti-aging compound, TFC-1326, has been highlighted in Stonegate Healthcare Partners’ latest research report. The publication, titled "Sirona Biochem’s TFC-1326 Clinical Data Versus Retinoid Clinical Data," provides an extensive evaluation of TFC-1326’s clinical trial performance, setting it apart from traditional retinoid treatments. The report outl...

 PRESS RELEASE

Sirona Biochem Announces Publication of Groundbreaking Study on TFC-13...

Sirona Biochem Announces Publication of Groundbreaking Study on TFC-1326 Compound in the Journal of Cosmetic Dermatology VANCOUVER, British Columbia, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) is proud to announce the publication of a pivotal research article in the prestigious Journal of Cosmetic Dermatology. About the Study The article, titled “TFC-1326 Compound Reduces Clinical Signs of Skin Aging: Evidence From In Vitro Human Adipose and Skin Models and Pilot Clinical Trial,” highlights the groundbreaking efficacy of Sirona’s proprietary compound ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch